Raymond James Financial Inc. Invests $135.93 Million in Sanofi (NASDAQ:SNY)

Raymond James Financial Inc. acquired a new stake in Sanofi (NASDAQ:SNY - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 2,818,429 shares of the company's stock, valued at approximately $135,933,000. Raymond James Financial Inc. owned about 0.11% of Sanofi as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the business. Franklin Resources Inc. increased its stake in shares of Sanofi by 13.1% in the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company's stock valued at $208,106,000 after buying an additional 395,744 shares during the period. Natixis Advisors LLC increased its stake in shares of Sanofi by 4.1% in the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company's stock valued at $165,640,000 after buying an additional 114,133 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock valued at $133,172,000 after buying an additional 399,301 shares during the period. DAVENPORT & Co LLC increased its stake in shares of Sanofi by 40.7% in the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock valued at $110,715,000 after buying an additional 664,455 shares during the period. Finally, Jennison Associates LLC grew its stake in shares of Sanofi by 938.0% during the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company's stock worth $109,753,000 after purchasing an additional 1,720,972 shares during the period. Institutional investors own 14.04% of the company's stock.

Remove Ads

Sanofi Trading Down 0.3 %

SNY stock traded down $0.17 during midday trading on Friday, hitting $59.25. 3,783,298 shares of the company's stock were exchanged, compared to its average volume of 2,598,733. The stock's fifty day moving average price is $52.65 and its 200-day moving average price is $52.75. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The company has a market cap of $150.37 billion, a PE ratio of 23.80, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a one year low of $45.22 and a one year high of $59.72.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Research analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Finally, StockNews.com cut Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.